

Freedom of Information Request

Q1. How many patients have you treated (using surgery, radiotherapy or any systemic anti-cancer therapy) in the last three months for:

- **Breast cancer (any stage)**
- **Early breast cancer (both early-stage and locally advanced, inclusive of stages I-IIIc)**
- **Metastatic breast cancer (stage IV)**

Review of diagnostic codes has established that there were 153 Breast cancers (any stage) treated in the three months March to May 2021. We have determined again using coding that 75 of these were early breast cancer and the remaining 78 was more advanced breast cancer.

Q2. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- **Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)**
- **Abemaciclib + Fulvestrant**
- **Anthracycline (e.g. doxorubicin or epirubicin) as a single agent**
- **Atezolizumab +Nab-paclitaxel/Paclitaxel**
- **Capecitabine as a single agent**
- **Carboplatin or Cisplatin as a single agent**
- **Eribulin as a single agent or in combination**
- **Everolimus + Exemestane**
- **Fluorouracil**
- **Fulvestrant as a single agent**
- **Lapatinib**
- **Neratinib**
- **Olaparib**
- **Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)**
- **Palbociclib + Fulvestrant**
- **Pertuzumab + Trastuzumab + Docetaxel**
- **Platinum (e.g. carboplatin or cisplatin) as a single agent**
- **Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)**
- **Ribociclib + Fulvestrant**
- **Talazoparib**



- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Transtuzumab as a single agent or in combination
- Trastuzumab emtansine
- Any other active systemic anti-cancer therapy

See below.

Number of patients treated in Laurel House for breast cancer (any stage) in the past 3 months (01/03/2021-31/05/2021) with the following systemic anti-cancer therapies:	
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	2
Abemaciclib + Fulvestrant	4
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	2
Atezolizumab +Nab-paclitaxel/Paclitaxel	1
Capecitabine as a single agent	6
Carboplatin or Cisplatin as a single agent	4
Eribulin as a single agent or in combination	2
Everolimus + Exemestane	0
Fluorouracil	17
Fulvestrant as a single agent	8
Lapatinib	0
Neratinib	2
Olaparib	0
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	29
Palbociclib + Fulvestrant	3
Pertuzumab + Trastuzumab + Docetaxel	21
Platinum (e.g. carboplatin or cisplatin) as a single agent	4 (same as line 7 above)
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	0
Ribociclib + Fulvestrant	0
Talazoparib	0
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	39
Transtuzumab as a single agent or in combination	43
Trastuzumab emtansine	1
Any other active systemic anti-cancer therapy*	
*Vinorelbine	11
*Cyclophosphamide +Docetaxel	1
*Epirubicin in combination with Cyclophosphamide and taxane	13